top of page

Free Biopharma Daily Stock Updates - 09/01/21

  • Writer: BPIQ
    BPIQ
  • Sep 1, 2021
  • 2 min read

$XBI $135.08 +1.70%

Covid Updates

$RIGL +8.2% Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases source


$MRNA +3.5% Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster source


Pipeline Updates

$VALN -4.7% Valneva to Participate in Goldman Sachs Eleventh Annual Biotech Symposium source


$IMMP -4.0% Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients

in TACTI-002 source


$BLCM +17.0% Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch source


$INMB +0.6% Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination source


$ASMB +2.6% Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158 source


$IBRX +3.7% ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting source


$CHRS +0.9% Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma source


$RVNC +1.2% Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery source


$MRSN +0.30% Mersana Therapeutics to Provide Update on the Progress of its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I Study source


$AYLA +4.0% Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 source


$XERS +1.5% XERIS PHARMACEUTICALS COMPLETES ENROLLMENT OF ITS PHASE 1 STUDY OF LEVOTHYROXINE (XP-8121) source


$BCRX +1.4% U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile source


$ZNTL -1.6% Zentalis Pharmaceuticals Announces Publication In The Journal Of Medicinal Chemistry Highlighting The Discovery Of Its Wee1 Inhibitor Candidate Zn-c3 source


$AXGN +1.8% axogen recon(sm) clinical study completes subject follow-up source


$AUTL +4.0% Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology source


Posted by JM

 
 
 

Comments

bottom of page